Akari Therapeutics formalizes interim CEO compensation: $50k/month in equity, no cash/benefits/severance

Akari Therapeutics Plc

Samir R. Patel appointed Interim President & CEO effective May 1; agreement signed May 31.
Compensation entirely equity-based: $50,000/month in fully vested ordinary shares valued at monthly closing price.
No annual bonus, employee benefits, or severance entitlements; at-will independent contractor role.
Company may terminate agreement immediately for any reason.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Samir R. Patel

Interim President and Chief Executive Officer

AKTX · Akari Therapeutics Plc

Effective: 2024-05-01
Filed: June 5, 2024, 7:59 PM ET

As previously disclosed, on April 25, 2024, the board of directors (the “Board”) of Akari Therapeutics, Plc (the “Company”) appointed Samir R. Patel, M.D., a member of the Board, as Interim President and Chief Executive Officer, effective May 1, 2024, to serve in such capacities until such time as determined by the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Samir R. Patel was appointed as Interim President and Chief Executive Officer at Akari Therapeutics Plc.

Action: appointed
Role: Interim President and Chief Executive Officer

Exact text from the filing

As previously disclosed, on April 25, 2024, the board of directors (the “Board”) of Akari Therapeutics, Plc (the “Company”) appointed Samir R. Patel, M.D., a member of the Board, as Interim President and Chief Executive Officer, effective May 1, 2024, to serve in such capacities until such time as determined by the Board.

View on SEC.gov

Akari Therapeutics Plc filing history →

Source: SEC EDGAR

accession 0000950170-24-069414

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.